TR200901984T1 - Olmesartan medoksomil ve amlodipinin katı dozaj formu - Google Patents

Olmesartan medoksomil ve amlodipinin katı dozaj formu

Info

Publication number
TR200901984T1
TR200901984T1 TR2009/01984T TR200901984T TR200901984T1 TR 200901984 T1 TR200901984 T1 TR 200901984T1 TR 2009/01984 T TR2009/01984 T TR 2009/01984T TR 200901984 T TR200901984 T TR 200901984T TR 200901984 T1 TR200901984 T1 TR 200901984T1
Authority
TR
Turkey
Prior art keywords
solid dosage
dosage form
amlodipine
medoxomil
olmesartan
Prior art date
Application number
TR2009/01984T
Other languages
English (en)
Inventor
Bauer Wolfgang
Lichey Johann
Teubner Andreas
Wadenstorfer Elmar
Original Assignee
Daiichi Sankyo Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38754721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200901984(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Company Limited filed Critical Daiichi Sankyo Company Limited
Publication of TR200901984T1 publication Critical patent/TR200901984T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bu buluş, olmesartan medoksomil ve amlodipin ya da bunun farmakolojik olarak kabul edilebilen bir tuzunu içeren kararlı, katı bir dozaj formu ile ilgilidir. Özellikle de, indirgen şekerlerden muaf olan katı dozaj formları ile ilgilidir. Kararlı, katı dozaj formu isteğe bağlı olarak hidroklorotiazit ve bunun farmakolojik olarak kabul edilebilen bir tuzunu da içerebilmektedir.
TR2009/01984T 2006-09-15 2007-10-12 Olmesartan medoksomil ve amlodipinin katı dozaj formu TR200901984T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84509006P 2006-09-15 2006-09-15

Publications (1)

Publication Number Publication Date
TR200901984T1 true TR200901984T1 (tr) 2009-08-21

Family

ID=38754721

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2009/01984T TR200901984T1 (tr) 2006-09-15 2007-10-12 Olmesartan medoksomil ve amlodipinin katı dozaj formu

Country Status (22)

Country Link
US (2) US20090175942A1 (tr)
JP (1) JP5344620B2 (tr)
AT (1) AT509493B1 (tr)
AU (1) AU2007297333B2 (tr)
BR (1) BRPI0716893A2 (tr)
CH (1) CH703897B1 (tr)
DE (1) DE212007000063U1 (tr)
DK (1) DK200900369A (tr)
FI (1) FI124122B (tr)
GB (1) GB2454620B (tr)
IL (1) IL197518A0 (tr)
IS (1) IS8808A (tr)
MY (1) MY157716A (tr)
NZ (1) NZ575422A (tr)
PT (1) PT2008032107W (tr)
RU (1) RU2423975C2 (tr)
SE (1) SE0900332L (tr)
SK (1) SK288460B6 (tr)
TR (1) TR200901984T1 (tr)
TW (1) TWI399223B (tr)
WO (1) WO2008032107A1 (tr)
ZA (1) ZA200810616B (tr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2598449Y2 (ja) 1993-08-06 1999-08-09 株式会社ソミック石川 ボールジョイント
ES2510866T3 (es) 2008-03-13 2014-10-21 Daiichi Sankyo Company, Limited Mejora de la solubilidad de una preparación que contiene olmesartán medoxomilo
TW201000097A (en) * 2008-05-30 2010-01-01 Daiichi Sankyo Co Ltd Medicament for the prophylaxis or treament of hypertension
US20120115837A1 (en) * 2009-04-30 2012-05-10 Takeda Pharmaceutical Company Limited Solid Preparation
JP5719385B2 (ja) * 2010-02-24 2015-05-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ラミプリル及びベシル酸アムロジピンの固形医薬製剤及びその製造
EP2425859A1 (en) * 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
CN102028663B (zh) * 2010-12-14 2011-11-30 北京万生药业有限责任公司 一种稳定的奥美沙坦酯固体制剂
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
CN103565807B (zh) * 2012-07-25 2015-11-04 天津市汉康医药生物技术有限公司 一种奥美沙坦酯氨氯地平药物组合物
WO2014058047A1 (ja) * 2012-10-12 2014-04-17 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
JP5871984B2 (ja) * 2013-04-15 2016-03-01 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物
JPWO2014188729A1 (ja) * 2013-05-24 2017-02-23 持田製薬株式会社 経口用組成物
EP2883539A1 (en) 2013-12-12 2015-06-17 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of olmesartan and amlodipine
CN104739799B (zh) * 2013-12-27 2018-01-05 辰欣药业股份有限公司 一种用于直接压片的苯磺酸氨氯地平组合物及其片剂制备方法
KR102222917B1 (ko) * 2014-06-25 2021-03-05 한림제약(주) 암로디핀 및 올메사탄 메독소밀을 포함하는 약학 조성물
CN104997778A (zh) * 2015-07-08 2015-10-28 南京正大天晴制药有限公司 一种奥美沙坦酯氨氯地平药物组合物
CN105902510A (zh) * 2015-12-24 2016-08-31 嘉实（湖南）医药科技有限公司 一种奥美沙坦酯氨氯地平复方制剂的制备工艺
AU2020229265B2 (en) * 2019-02-26 2023-09-14 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
CN115300476B (zh) * 2022-09-01 2024-04-16 华润双鹤药业股份有限公司 一种药物组合物及其制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3025292A (en) 1962-03-13 Reduction of i
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4772596A (en) * 1986-10-09 1988-09-20 Sankyo Company Limited Dihydropyridine derivatives, their preparation and their use
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5260285A (en) * 1990-12-07 1993-11-09 Merck & Co., Inc. Substituted imidazopyridazines as angiotensin II antagonists
US5250521A (en) * 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5238942A (en) * 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
JPH05967A (ja) * 1991-06-19 1993-01-08 Yamanouchi Pharmaceut Co Ltd 組織プラスミノーゲンアクチベーター含有製剤組成物
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
FR2688781B1 (fr) * 1992-03-23 1994-07-01 Sanofi Elf Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
GB9405833D0 (en) * 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine
US5952006A (en) * 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6036977A (en) * 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
US5808084A (en) * 1996-02-14 1998-09-15 Pfizer, Inc. Process for the preparation of 1,4-dihydropyridinedicarboxylic esters
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
US6420412B2 (en) * 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
HU225415B1 (en) * 1996-07-15 2006-11-28 Sankyo Co Medicinal compositions comprising cs-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma
JP4475685B2 (ja) * 1997-06-27 2010-06-09 スミスクライン・ビーチャム・コーポレイション エプロサルタン・一水和物
US6630498B2 (en) * 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
US20010044584A1 (en) * 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US20030022928A1 (en) * 1998-03-11 2003-01-30 Smithkline Beecham Corporation Novel compositions of eprosartan
US20020127254A1 (en) * 1998-06-25 2002-09-12 Lavipharm Laboratories Inc. Devices for local and systemic delivery of active substance and methods of manufacturing thereof
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
CA2368083A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
JP2001089393A (ja) * 1999-07-21 2001-04-03 Takeda Chem Ind Ltd 脳血管障害の再発予防剤および脳血管障害の後遺症の改善・進展抑制剤
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
BR0109991A (pt) * 2000-04-11 2003-05-27 Sankyo Co Composição farmacêutica
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
WO2002043807A2 (en) * 2000-12-01 2002-06-06 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
EP1413315A4 (en) * 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
US6680334B2 (en) * 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
JP2005508358A (ja) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
JP3874419B2 (ja) * 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
HUP0301537A3 (en) * 2003-06-03 2005-07-28 Egis Gyogyszergyar Nyilvanosan Deramcyclane fumarate tablets and process for producing them
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
WO2005070463A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
KR20090102883A (ko) * 2004-09-02 2009-09-30 테바 파마슈티컬 인더스트리즈 리미티드 올메살탄 메독소밀의 정제
JP2006176496A (ja) * 2004-11-24 2006-07-06 Freunt Ind Co Ltd 固形剤およびその製造方法
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
JP2007526342A (ja) * 2005-01-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド 低レベルの不純物を有するオルメサルタンメドキソミル
CN101160126A (zh) * 2005-04-20 2008-04-09 默克公司 血管紧张肽ⅱ受体拮抗剂
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法
KR20070009851A (ko) * 2005-07-14 2007-01-19 씨제이 주식회사 클로피도그렐 황산수소염 함유 약학 조성물
ES2393117T3 (es) * 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
WO2007062338A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
JP2007145646A (ja) * 2005-11-28 2007-06-14 Asahi Glass Co Ltd プレス成型装置及びプレス成型装置の搬送品搬送方法
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.

Also Published As

Publication number Publication date
RU2009114166A (ru) 2010-10-20
WO2008032107A1 (en) 2008-03-20
GB2454620A (en) 2009-05-13
TWI399223B (zh) 2013-06-21
US20160129008A1 (en) 2016-05-12
NZ575422A (en) 2011-01-28
GB2454620B (en) 2011-08-17
FI124122B (fi) 2014-03-31
FI20090094L (fi) 2009-03-13
TW200817052A (en) 2008-04-16
SE0900332L (sv) 2009-06-12
HK1127282A1 (en) 2009-09-25
AT509493A5 (de) 2011-09-15
ZA200810616B (en) 2009-08-26
MY157716A (en) 2016-07-15
AU2007297333A1 (en) 2008-03-20
SK50212009A3 (sk) 2009-06-05
AT509493B1 (de) 2012-01-15
GB0903844D0 (en) 2009-04-22
RU2423975C2 (ru) 2011-07-20
BRPI0716893A2 (pt) 2014-05-06
IS8808A (is) 2009-03-12
IL197518A0 (en) 2009-12-24
SK288460B6 (sk) 2017-03-01
DE212007000063U1 (de) 2009-05-14
JP5344620B2 (ja) 2013-11-20
US20090175942A1 (en) 2009-07-09
JP2011500505A (ja) 2011-01-06
DK200900369A (en) 2009-03-16
CH703897B1 (de) 2012-04-13
PT2008032107W (pt) 2013-07-09
AU2007297333B2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
GB2454620A (en) Solid dosage form of olmesartan medoxomil and amlodipine
FR20C1019I2 (fr) Promedicaments de composes de 2,4-pyrimidinediamine et leurs utilisations
EP2340038A4 (en) BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE
EP1943341A4 (en) BLOOD-BRAIN-SPEED-EPITOPES AND USES THEREOF
BR122013025375B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
BRPI0810813A2 (pt) Agentes anti-hipertensivos de ação dupla
EP1937824A4 (en) TRNA COMPOSITIONS AND ITS USES
BRPI0924137A2 (pt) composição farmacêutica sólida compreendendo amlodipina e losartan com melhor estabilidade
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI0905369A2 (pt) Composição farmacêutica, composição e kit compartimentado
EP1948798A4 (en) Anti-alpha2 integrin antibodies and their uses
EP2356228A4 (en) BLOCK COPOLYMERS AND USES THEREOF
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0915897A2 (pt) compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
EP2361097A4 (en) SCR-HEMMER WITH PEPTIDES DERIVED FROM NA / K ATPASE AND OUABINE ANTAGONISTS AND APPLICATIONS THEREOF
BRPI0822221A2 (pt) Composições aquosas e estáveis de ciclosporina
BRPI0822337A2 (pt) Folatos, composições e usos dos mesmos
EP2405886A4 (en) TOPICAL BODY CARE AND PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS THEREOF
EP2040747A4 (en) SOLUBLE STABILIZED TRIMERS HIV CREAM PROTEINS AND ITS USE
FR2884516B1 (fr) Antagonistes npy, preparation et utilisations
EP2099441A4 (en) METAL DISPENSER AND ITS THERAPEUTIC USES
EP2288615A4 (en) SELECTIVE CASPASE HEMMER AND ITS USE
EP1924143A4 (en) O-NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
FR2917418B1 (fr) Composition de securite, non photocopiable et authentifiable